Sarepta Therapeutics Inc (BSP:S1RP34)
R$ 37.72 -0.52 (-1.36%) Market Cap: 72.06 Bil Enterprise Value: 73.29 Bil PE Ratio: 78.90 PB Ratio: 9.50 GF Score: 79/100

Sarepta Therapeutics Inc at Evercore ISI HealthCONx Conference (Virtual) Transcript

Dec 02, 2020 / 08:30PM GMT
Release Date Price: R$38.47 (+3.47%)
Maneka Mirchandaney
Evercore ISI Institutional Equities, Research Division - Analyst

Great. Good afternoon, everyone. I'm Maneka Mirchandaney from the Evercore ISI biotech team. I am really pleased to be here with Sarepta. We've got Doug Ingram, who's its President and CEO; and Ian Esteban, who's SVP, Chief of Staff and Corporate Affairs. Thank you both so much for being here today. And Doug, to start -- just give us a broad sense for where Sarepta is now? And what the vision is for the next few years?

Questions & Answers

Douglas S. Ingram
Sarepta Therapeutics, Inc. - President, CEO & Director

Sure. Thank you very much, and thanks for having us today. I mean if I started -- its most -- its broadest sense. We have to consider the fact we're a rare disease company focused on genetic medicine to treat disease and bring a better life to patients. There are 7,000 rare diseases that exist. 80% of them are single-gene mutations, which means they are really prime candidates for the intervention of genetic medicine. As we sit here today, only 5% of those

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot